Request Full Dossier (PDF)
The complete Clinical Dossier - including formulation rationale, dose-response data, ingredient safety profiles, contraindications, and study citations - is available on request to healthcare professionals and researchers.
What's in the dossier
- Formulation rationale - why these 5 ingredients in these doses.
- Dose-response data for each active.
- Safety profile per ingredient with reference to LD50 and chronic-use studies.
- Drug interaction screening against major GLP-1 agonists and common medications.
- Contraindication list (pregnancy, kidney disease, etc.).
- Full citation index with PubMed links.
Quick safety summary
- All 5 ingredients have established safety profiles at the clinical doses used.
- No known interactions with semaglutide, tirzepatide, or related GLP-1 agonists at the doses in MYOTIDE.
- Not recommended during pregnancy or breastfeeding (consult prescribing physician).
- Not recommended for individuals with severe kidney disease.
- Mild digestive adjustment (slight bloating, stool changes) possible in the first 3-5 days.
Working in research?
If you're conducting independent research on GLP-1 side-effect management and would like to discuss MYOTIDE as a study supplement, please get in touch via our contact form.